IceCube, the Antarctic neutrino detector that in July of 2018 helped unravel one of the oldest riddles in physics and astronomy — the origin of high-energy neutrinos and cosmic rays — is getting an upgrade. This month, the National Science Foundation (NSF) approved $23 million in funding to expand the detector and its scientific capabilities. Seven new strings of optical modules will be added to the 86 existing strings, adding more than 700 new, enhanced optical modules to the 5,160 sensors already embedded in the ice beneath the geographic South Pole.
Acetaminophen—the active ingredient in many Americans’ go-to pain reliever, Tylenol—typically stems from a surprising source: coal tar, a viscous liquid produced when oxygen-deprived coal is subjected to high heat. But a new method developed by researchers at the University of Wisconsin–Madison’s Great Lakes Bioenergy Research Center (GLBRC) offers an environmentally friendly alternative to this fossil fuel-heavy process, drawing on a natural compound derived from plant material to synthesize the popular medication.
Headquartered at the University of Wisconsin-Madison, IceCube uses thousands of these sensors embedded in a cubic kilometer of ice underneath the South Pole to track neutrinos, invisible subatomic particles that traverse space at nearly the speed of light. The sensors, called digital optical modules, or DOMs, detect the flash of blue light created when a neutrino crashes into a molecule of ice.
Waisman Center Launches New Fund to Advance Intellectual and Developmental Disabilities Genomics Research
The fund, named the Mailick and Messing Interdisciplinary Research Fund, honors former center directors, Marsha Mailick, PhD (2001-2014) and Albee Messing, VMD, PhD (2014-2018). Their commitment to interdisciplinary research on intellectual and developmental disabilities and neurodegenerative diseases laid the groundwork for the Functional Genetics/Genomics of Neurodevelopmental and Neurodegenerative Diseases cluster, one of the first six clusters selected by the campus cluster hire program for funding.
Having celebrated its 25th year in 2018, Journey North, one of North America’s largest citizen science programs, is celebrating another milestone this year by moving to the UW–Madison Wisconsin’s Arboretum.
Bradfield, a UW-Madison Professor of Oncology, had been serving as the center's interim director since August 2018. He reports to the Vice Chancellor for Research and Graduate Education. The Biotechnology Center was founded in 1984 by McArdle Laboratory for Cancer Research emeritus faculty member Richard Burgess, who also served as director for its first 12 years.
By Jordana Lenon, UW-Madison Stem Cell and Regenerative Medicine Center As gene editing therapies for macular degeneration and other visual disorders work their way into clinical trials, the University of Wisconsin–Madison is on the forefront of research into making sure they are safe and effective. Nine years ago, David Gamm,…
Since University of Wisconsin–Madison researcher James Thomson and colleagues derived the first human embryonic stem cells 20 years ago, research universities and biotechnology companies around the globe have worked to unlock their vast potential. Through the work of theUW-Madison Stem Cell and Regenerative Medicine Center , UW–Madison has remained at the forefront of the field.
Longtime director of the UW–Madison Biotechnology Center, Mike Sussman, has announced that he is stepping down from that position to serve as director of the Genome Center of Wisconsin, located within the Biotechnology Center. “With DNA analysis now permeating all aspects of research, our economy, and our lives, aggressive attention…